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We treated six patients who had relapsed after intensive chemotherapy, presenting initially with AML
or RAEB, a hypocellular marrow and normal karyotype, and who were deemed unsuitable for
re-induction with intensive chemotherapy, with low dose oral melphalan. Three of six patients
achieved complete hematological response with no signiﬁcant toxicity and with a duration of
12, 8 and 3þ months respectively. These three patients had received only two prior courses
of chemotherapy each, in contrast to non-responders who were more heavily pre-treated. Low dose
melphalan is highly effective therapy for this rare subtype of AML/RAEB, even in relapsed disease with
limited prior chemotherapy.
& 2012 Elsevier Ltd.Open access under CC BY-NC-ND license.Low dose melphalan is a highly effective and well-tolerated
treatment in a selected group of patients with Acute Myeloid
Leukemia (AML) or Refractory Anemia with Excess Blasts (RAEB)
unﬁt for intensive chemotherapy. Durable complete remissions
(CR) have usually been obtained in patients with hypocellular
marrow and normal cytogenetics, with a typical CR1 lasting 12
months 1 A total of 98 patients have been reported in 6 studies,
of which 75 had a diagnosis of RAEB and 23 a diagnosis of
AML (secondary or with dysplasia)1–6. No patient had received
prior intensive chemotherapy, but 8 patients had received low
dose chemotherapy (cytarabine, danazol or mercaptopurine)
prior to melphalan treatment. Fifty one responses were recorded
of which 31 were complete remissions. Ease of administration,
good side effect proﬁle and low cost make it an attractive option.
Melphalan is a cytotoxic alkylating agent, although the mechan-
ism of action in MDS/AML remains unclear. Mild worsening of
baseline cytopenias precedes responses but the pharmacody-
namics is not typical for conventional chemotherapeutic agents
in these disorders. All studies described used a schedule of
2 mg daily oral melphalan. Re-treatment usually produces atology, Bexley Wing, Leeds
of Oncology, Leeds LS9 7TF,
13 2068177.
-NC-ND license.second CR of shorter duration. Further re-treatment is rarely able
to produce CR3 and at the point of chemoresistance most patients
have a 17p deletion/TP53mutation5 This observation should perhaps
restrict melphalan to elderly patients with RAEB/AML and/or those
whose goal for treatment is primarily improved quality of life.
We have now treated six patients with low dose melphalan,-
who presented at initial diagnosis (between 2005 and 2011)
with AML/RAEB, a hypocellular marrow and normal karyotype
and who had relapsed following initial induction of complete
remission with standard intensive chemotherapy. Bone marrow
trephine biopsy cellularity was assessed in a single diagnostic
laboratory as low for the patient’s age and was always o50%.
No patients had molecular analyses performed. All were deemed
either unﬁt for re-induction with intensive chemotherapy or
declined intensive treatment. Verbal informed consent was given
in all cases. Three patients achieved a complete hematological
response to oral melphalan (Table 1).
Patient 1 was aged 73 years with AML. Her initial chemother-
apy was daunorubicin, clofarabine (DClo) and gemtuzumab
ozogamycin on the Leukemia Research Fund AML16 trial. CR1
was documented after course 1. Following course 2 (DClo only)
she developed severe sepsis and acute renal injury requiring
temporary dialysis. Further consolidation chemotherapy was
deemed unsafe. CR1 lasted 17 months. The relapse marrow was
hypocellular with a normal karyotype. She declined further
Table 1
Hematological data and response of six patients with relapsed AML/RAEB treated with low dose melphalan.
Patient Pre-treatment blood counts Peak post-treatment blood counts Response CR2 Duration (months)
Hb (g/dl) ANC (109/l) Platelets (109/l) Hb (g/dl) ANC (109/l) Platelets (109/l)
1 8.7 0.6 79 11.5 5.6 267 CR 12
2 7.9 0.3 51 14.1 9.3 215 CR 8
3 9.7 1.7 13 9.2 0.14 7 NR
4 7.7 0.23 27 10.1 1.13 70 Transient and partial
5 9.9 0.19 159 9.7 0.15 15 NR
6 12.1a 0.6 53 12.3 2.5 141 CR 3þ
a Only post transfusion hemoglobin available.
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response with eight weeks of oral melphalan 2 mg daily without
side effects. Hematological relapse was noted after 12 months and
another complete hematological response was obtained with
further re-induction with melphalan. This lasted for 6 months
and attempted re-induction with melphalan was then unsuccess-
ful. She has received supportive care with 3-weekly red cell and
clinically-driven platelet transfusions.
Patient 2, a 54-year-old man with RAEB 2, and severe chronic
obstructive pulmonary disease, struggled through induction
chemotherapy with daunorubicin plus cytarabine (DA) 3þ10.
Second DA 3þ8 produced delayed hematopoietic recovery. CR1
was documented after course 1 and lasted 18 months. Relapse
was normo/hypocellular with normal karyotype. He declined
further intensive therapy and was considered unsuitable for
allogeneic stem cell transplantation due to poor pulmonary and
cardiac function. He was treated with oral melphalan 2 mg daily
for 11 weeks and achieved complete hematological response of
8 months duration. He has since been maintained on supportive
care with 2-weekly red cell transfusions for over 12 months.
Patient 3 presented at age 62 with RAEB 1 and a history of
diabetes mellitus, hypertension, prostatic carcinoma and coronary
artery by-pass graft. He achieved CRi (dysplastic) with DA 3þ10.
Delayed hematopoietic recovery after DA 3þ8 prevented further
consolidation chemotherapy. He relapsed after six months with
normocellular RAEB 1 with normal karyotype. After ﬁve cycles of
azacitidine, marrow examination showed transformation to AML
(normal karyotype). Further intensive chemotherapy with ADE
(daunorubicin, cytarabine, and etoposide) led to life threatening
invasive fungal infection and myocardial infarction. Marrow
examination was severely hypocellular but with o5% blasts. He
remained heavily transfusion dependent and ten months later an
increase in peripheral blasts was noted. In an attempt to improve
hematopoietic function he was treated with melphalan 2 mg daily
for four weeks without side effects. No response was noted and
melphalan was stopped. He was maintained on supportive care
alone for 18 months with weekly red cell and platelet transfu-
sions and frequent hospitalization for infection.
Patient 4 a 60-year-old man presented with AML. Despite
severe emphysema he was treated with induction chemotherapy
with DA 3þ10, followed by DA 3þ8 and MACE (mitoxantrone,
cytarabine, amsacrine) consolidation on the Medical Research
Council AML15 trial. Delayed hematopoietic recovery prevented
the planned fourth course of chemotherapy. CR1 was documented
after course 1 and lasted 17 months. Relapse was hypocellular
RAEB 1 (10% blasts) with normal karyotype. He was treated with
oral melphalan 2 mg for 6 weeks without hematological response
or complications requiring hospitalization as an in-patient. Eight
weeks post melphalan on supportive care only, he demonstrated
partial trilineage recovery. He became red cell transfusion inde-
pendent with hemoglobin concentration maintained at 410 g/dl.
His platelet count rose from 5–12109/l pre- and immediatelypost-melphalan to 65–70109/l, and his neutrophils rose
from 0.07–0.25109/l to 0.36–1.13109/l. Four weeks later,
he commenced three cycles of Azacitidine, which were compli-
cated by recurrent infections and progressive haematopoietic and
clinical deterioration. He was maintained on supportive care for a
further 8 months.
Patient 5 was a 57-year-old male with AML. He tolerated only
2 courses of DA (3þ10, followed by 3þ8) chemotherapy due to
hepatic candidiasis. He relapsed after CR1 duration of 6 years and
was re-induced with 2 courses of ADE (3þ5þ10, followed by
3þ5þ8) then intermediate dose cytarabine (1.5 g/m26 doses)
achieving CR2. Allogeneic stem cell transplant was discussed
but given signiﬁcant cardiac and respiratory comorbidity was
declined by both physician and patient. CR2 duration was 3 years.
At second relapse he declined further intensive chemotherapy.
He commenced melphalan 2 mg daily and received 7 weeks of
treatment. He was admitted with neutropenic sepsis twice in the
subsequent 4 weeks, declined further active treatment and died
peacefully in hospice care.
Patient 6 was a 69-year-old female with no co-morbid conditions
presenting with pancytopenia. RAEB-2 was diagnosed and she was
treated with DA 3þ10 then DA 3þ8. Prolonged hematopoietic
regeneration did not allow a consolidation block. CR1 duration was
12 months and relapse was again hypocellular with a normal
karyotype and 16% bone marrow blasts. She declined re-induction
with intensive chemotherapy and commenced low-dose oral mel-
phalan 2 mg daily for 12 weeks. She obtained a complete hemato-
logical response with no toxicity, one red cell transfusion and no
hospitalization. Bone marrow examination conﬁrmed CR2 with 1.9%
bone marrow blasts. She remains in CR2 of 3 months duration.
Low dose melphalan is an important option to consider in
older patients with de novo AML or RAEB who are unﬁt for
intensive chemotherapy and who present with a hypocellular
marrow and normal karyotype. We have demonstrated for the
ﬁrst time that this treatment can successfully induce a second
complete hematological response (and complete remission in the
one patient who had bone marrow conﬁrmation) even when
patients have received prior intensive chemotherapy, although
our preliminary data would suggest that low dose melphalan may
be most effective at ﬁrst relapse and in patients who have
received no more than two courses of intensive chemotherapy.
Three of our patients treated at ﬁrst relapse achieved complete
hematological normalization with no toxicity. Of our three more
heavily pre-treated patients, one had a delayed but transient
trilineage partial hematological response and the other two did
not respond. In terms of cost effectiveness, low dose melphalan is
by far the most cost effective therapy for remission induction in
AML/RAEB, with a total drug cost of approximately h40 (£35,
USD55), no hospitalization and limited myelosuppression. There
is no standard of care for low intensity therapy in relapsed RAEB/
AML and no substantive clinical trial data. Options may include
low dose cytarabine, hypomethylating agents, or molecularly
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hypocellular MDS/AML with excess blasts. Although the natural
history of relapsed hypocellular RAEB/AML may be relatively
indolent on supportive care, quality of life in complete remission
is normal and clearly superior to transfusion dependence. Whilst
low dose melphalan is suitable only for a relatively rare
AML/RAEB patient group (with consequent difﬁculties for clinical
trials in this subgroup), this therapy is not widely used and many
such patients are therefore not accessing an effective non-toxic
route to high quality life in complete remission, albeit with a
ﬁnite timescale.
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